AI Buyer Insights:

Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

Michelin, an e2open customer evaluated Oracle Transportation Management

Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

Michelin, an e2open customer evaluated Oracle Transportation Management

Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

List of Veeva Crossix DIFA Customers

loading spinner icon



Apply Filters For Customers

Logo Customer Industry Empl. Revenue Country Vendor Application Category When SI Insight
Amgen Life Sciences 28000 $33.4B United States Veeva Systems Veeva Crossix DIFA Marketing Analytics 2017 n/a
In 2017, Amgen implemented Veeva Crossix DIFA to centralize Marketing Analytics for its commercial brand and media measurement workflows. Veeva Crossix DIFA was deployed as a Marketing Analytics application to provide privacy-focused audience measurement and campaign analytics support for Amgen’s marketing and analytics teams. The implementation emphasized core Marketing Analytics capabilities, including audience segmentation, cross-channel measurement, campaign attribution workflows, and healthcare-compliant handling of de-identified patient information. Veeva Crossix DIFA was configured to ingest and normalize marketing and media signal data, and to produce analytic outputs that support planning and measurement use cases typical of pharmaceutical brand teams. Operational coverage targeted Amgen’s commercial marketing, media planning, and analytics functions, aligning measurement outputs with brand planning and media buy decision processes. The deployment incorporated data governance controls and privacy-first processes to ensure compliance with health data expectations, and the program included role-based access and structured reporting for marketing stakeholders. Governance and rollout focused on embedding the Marketing Analytics capability into existing campaign planning workflows, updating measurement governance, and equipping brand and analytics staff with new operational procedures for media measurement and audience insights. The implementation narrative centers on Veeva Crossix DIFA as the marketing analytics engine used to standardize healthcare audience measurement within Amgen’s commercial organization.
Dotdash, Inc. Professional Services 100 $30M United States Veeva Systems Veeva Crossix DIFA Marketing Analytics 2018 n/a
In 2018, Dotdash, Inc. implemented Veeva Crossix DIFA as a central component of its Marketing Analytics capabilities. Veeva Crossix DIFA was deployed to deliver pre to post sale insights for pharmaceutical accounts and to support revenue driven account strategies for major pharma clients including Novartis, GSK and AbbVie. The implementation emphasized campaign measurement, audience attribution, and health care audience linkage capabilities consistent with Marketing Analytics platforms. Configuration work produced campaign level reporting, custom performance decks, and analyst workflows that ingested Crossix DIFA outputs for seller enablement and campaign optimization. Teams used Veeva Crossix DIFA to surface audiences and attribution signals that informed creative targeting and media placement decisions. Integrations were operationalized with DoubleVerify, Google Analytics, MOAT, and proprietary data tools to consolidate viewability, site analytics, and ad verification metrics alongside Crossix DIFA's audience signals. The deployment operated cross functionally across marketing, editorial, digital production, analytics, research, product, ad ops, finance, development, offshore client success, and sales teams. Operational usage included direct analyst access for campaign analysis and shared reporting used in client facing presentations. Governance and rollout were led through account strategy and onboarding routines, with staff training and peer mentoring part of the operating model. The account lead maintained 14 accounts as the seller and account strategist for five months in 2018, managed a 7.5 million dollar book of business for major pharma clients, and led product training for new sales and marketing team members. Reported outcomes include incremental revenue captured in 2019 in excess of 1 million dollars to date and a quarterly performance movement from 101 percent to 113 percent by capturing an incremental 150 thousand dollars.
Gilead Sciences Life Sciences 17600 $28.8B United States Veeva Systems Veeva Crossix DIFA Marketing Analytics 2017 n/a
In 2017, Gilead Sciences implemented Veeva Crossix DIFA as a Marketing Analytics platform. The rollout established Veeva Crossix DIFA as a cloud-hosted analytics layer focused on healthcare and life sciences measurement, supporting brand and commercial analytics use cases within the organization. The implementation emphasized core Marketing Analytics capabilities including deterministic identity resolution, audience segmentation, media measurement, and campaign attribution, with the Veeva Crossix DIFA application providing the analytics and modelling engines for these functions. Reporting and visualization capabilities were configured to support campaign-level and audience-level analysis, enabling standardized marketing measurement workflows. Operational integration centered on embedding Veeva Crossix DIFA into marketing and commercial analytics processes, with data ingestion pipelines feeding deidentified healthcare signals into the platform and outputs routed to activation and reporting workflows. The architecture positioned Veeva Crossix DIFA as a centralized analytics service that interfaced with internal marketing systems and media channels through data exchange and standardized exports. Governance and process changes accompanied the deployment, instituting privacy controls and data stewardship practices to manage healthcare-sensitive data within marketing operations. Veeva Crossix DIFA was used to operationalize measurement governance, formalize campaign measurement processes, and consolidate cross-channel audience analytics for Gilead Sciences.
Life Sciences 69310 $42.2B United Kingdom Veeva Systems Veeva Crossix DIFA Marketing Analytics 2021 n/a
Professional Services 100 $15M United States Veeva Systems Veeva Crossix DIFA Marketing Analytics 2018 n/a
Professional Services 1000 $120M United States Veeva Systems Veeva Crossix DIFA Marketing Analytics 2016 n/a
Life Sciences 138100 $88.8B United States Veeva Systems Veeva Crossix DIFA Marketing Analytics 2017 n/a
Professional Services 13000 $300M United States Veeva Systems Veeva Crossix DIFA Marketing Analytics 2017 n/a
Professional Services 3000 $615M United States Veeva Systems Veeva Crossix DIFA Marketing Analytics 2017 n/a
Showing 1 to 9 of 9 entries

Buyer Intent: Companies Evaluating Veeva Crossix DIFA

ARTW Buyer Intent uncovers actionable customer signals, identifying software buyers actively evaluating Veeva Crossix DIFA. Gain ongoing access to real-time prospects and uncover hidden opportunities. Companies Actively Evaluating Veeva Crossix DIFA for Marketing Analytics include:

  1. Tripadvisor, a United States based Professional Services organization with 2850 Employees
  2. Millennium, a United States based Banking and Financial Services company with 6100 Employees

Discover Software Buyers actively Evaluating Enterprise Applications

Logo Company Industry Employees Revenue Country Evaluated
No data found
FAQ - APPS RUN THE WORLD Veeva Crossix DIFA Coverage

Veeva Crossix DIFA is a Marketing Analytics solution from Veeva Systems.

Companies worldwide use Veeva Crossix DIFA, from small firms to large enterprises across 21+ industries.

Organizations such as Johnson & Johnson, GSK, Amgen, Gilead Sciences and Starcom Mediavest Group, Inc. are recorded users of Veeva Crossix DIFA for Marketing Analytics.

Companies using Veeva Crossix DIFA are most concentrated in Life Sciences and Professional Services, with adoption spanning over 21 industries.

Companies using Veeva Crossix DIFA are most concentrated in United States and United Kingdom, with adoption tracked across 195 countries worldwide. This global distribution highlights the popularity of Veeva Crossix DIFA across Americas, EMEA, and APAC.

Companies using Veeva Crossix DIFA range from small businesses with 0-100 employees - 22.22%, to mid-sized firms with 101-1,000 employees - 11.11%, large organizations with 1,001-10,000 employees - 11.11%, and global enterprises with 10,000+ employees - 55.56%.

Customers of Veeva Crossix DIFA include firms across all revenue levels — from $0-100M, to $101M-$1B, $1B-$10B, and $10B+ global corporations.

Contact APPS RUN THE WORLD to access the full verified Veeva Crossix DIFA customer database with detailed Firmographics such as industry, geography, revenue, and employee breakdowns as well as key decision makers in charge of Marketing Analytics.